Bacterial meningitis in children

Lancet

Volumn 361, Issue 9375, 2003, Pages 2139-2148

  Sáez Llorens, Xavier ^a   McCracken Jr , George H ^b  

^a UNIVERSIDAD DE PANAMÁ   (Panama)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL VACCINE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DEXAMETHASONE; GARENOXACIN; GATIFLOXACIN; GENTAMICIN; HAEMOPHILUS VACCINE; MENINGOCOCCUS VACCINE; MEROPENEM; MOXIFLOXACIN; NAFCILLIN; OFLOXACIN; PENICILLIN G; PROTEIN C; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RIFAMPICIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTHRITIS; BACTERIAL MENINGITIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; ECONOMIC ASPECT; EPIDEMIC; ESCHERICHIA COLI; GANGRENE; HAEMOPHILUS INFLUENZAE; HUMAN; HYDROCEPHALUS; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; LUMBAR PUNCTURE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEIZURE; SEPSIS; SHOCK; SUBDURAL EFFUSION; TREATMENT OUTCOME; VACCINATION;

EID: 0037862949     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13693-8     Document Type: Conference Paper

References (111)

1. Sáez-Llorens X., McCracken G.H. Jr. Bacterial meningitis in neonates and children. Infect Dis Clin North Am. 4:1990;623-644.
2. Neuman H.B., Wald E.R. Bacterial meningitis in childhood at the Children′s Hospital of Pittsburgh: 1988-1998. Clin Pediatr (Phila). 40:2001;595-600.
3. Sande M.A., Tauber M.G., Scheld M., McCracken G.H. Jr. Pathophysiology of bacterial meningitis: summary of the workshop. Pediatr Infect Dis. 8:1989;929-933.
4. Sáez-Llorens X., Ramilo O., Mustafa M.M., et al. Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr. 116:1990;671-684.
5. Leib S.L., Tauber M.G. Pathogenesis of bacterial meningitis. Infect Dis Clin North Am. 13:1999;527-548.
6. Pfister H.W., Fontana A., Tauber M.G., et al. Mechanisms of brain injury in bacterial meningitis: workshop summary. CID. 19:1994;463-499.
7. Braun J.S., Tuomanen E.I. Molecular mechanisms of brain damage in bacterial meningitis. Adv Pediatr Infect Dis. 14:1999;49-71.
8. Peltola H. Worldwide H influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 13:2000;302-317.
9. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children: United States, 1998-2000. MMWR. 51:2002;234-239.
10. Black S.B., Shinefield H., Fireman B., et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 19:2000;187-195.
11. Di Fabio J.L., Castañeda E., Agudelo C.I., et al. Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America, Sireva-Vigia Group, 1993 to 1999. Pediatr Infect Dis J. 20:2001;959-967.
12. De Kleijn E.D., de Groot R., Lafeber A.B., et al. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J Infect Dis. 184:2001;98-102.
13. Lingappa J.R., Rosenstein N., Zell E.R., et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 19:2001;4566-4575.
14. Rennels M.B., Edwards K.M., Keyserling H.L., et al. Safety and immunogenicity of four doses of Neisseria meningitides group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 20:2001;153-159.
15. Sáez-Llorens X., McCracken G.J. Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am. 13:1999;619-636.
16. Moreno M.T., Vargas S., Poveda R., Sáez-Llorens X. Neonatal sepsis and meningitis in a developing Latin American country. Pediatr Infect Dis J. 13:1994;516-520.
17. Kessler S.L., Dajani A.S. Listeria meningitis in infants and children. Pediatr Infect Dis. 9:1990;61-63.
18. Linnan M.J., Mascola L., Lou X.D., et al. Epidemic listeriosis associated with Mexican-style cheese. N Engl J Med. 319:1988;823-828.
19. Nelson J.D. Cerebrospinal fluid shunt infections. Pediatr Infect Dis. 3:1984;530-532.
20. Diaz J.M., Catalan L., Urrutia M.T., et al. Trends of etiology of acute bacterial meningitis in Chilean children from 1989 to 1998. Impact of the anti-H influenzae type b vaccine. Rev Med Chil. 129:2001;719-726.
21. Adams W.G., Deaver K.A., Cochi S.L., et al. Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era. JAMA. 269:1993;221-226.
22. Pallares R., Viladrich P.F., Linares J., Cabellos C., Gudiol F. Impact of antibiotic resistance on chemotherapy for pneumococcal infections. Microb Drug Resist. 4:1998;339-347.
23. Tikhomirov E. Meningococcal meningitis: global situation and control measures. World Health Stat Q. 40:1987;98-109.
24. Riedo F.X., Plikaytis B.D., Broome C.V. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J. 14:1995;643-657.
25. Klein J.O., Feigin R.D., McCracken G.H. Jr. Report of the task force on diagnosis and management of meningitis. Pediatrics. 78:1986;959-982.
26. Fraser D.W., Darby C.P., Koehler R.E., et al. Risk factors in bacterial meningitis. J Infect Dis. 127:1973;271-277.
27. Baltimore R.S., Jenson H.B. Meningococcal vaccine: new recommendations for immunization of college freshmen. Curr Opin Pediatr. 13:2001;47-50.
28. Shapiro E.D. Prophylaxis for contacts of patients with meningococcal or Haemophilus influenzae type b disease. Pediatr Infect Dis. 1:1982;132-138.
29. Mertsola J., Ramilo O., Mustafa M.M., et al. Release of endotoxin after antibiotic treatment of gram negative bacterial meningitis. Pediatr Infect Dis. 8:1989;904-906.
30. Arditi M., Ables L., Yogev R. Cerebrospinal fluid endotoxin levels in children with H influenzae meningitis before and after administration of intravenous ceftriaxone. J Infect Dis. 160:1989;1005-1011.
31. Ramilo O., Sáez-Llorens X., Mertsola J., et al. Tumor necrosis factor a/cachectin and interleukin-1β initiate meningeal inflammation. J Exp Med. 172:1990;497-507.
32. Mustafa M.M., Ramilo O., Sáez-Llorens X., et al. Cerebrospinal fluid prostaglandins, interleukin-1β and tumor necrosis factor in bacterial meningitis: clinical and laboratory correlations in placebo and dexamethasone-treated patients. Am J Dis Child. 144:1990;883-887.
33. Fishman R.A. Brain edema. N Engl J Med. 193:1975;706-711.
34. Tauber M.C. Brain edema, intracranial pressure, and cerebral blood flow in bacterial meningitis. Pediatr Infect Dis. 8:1989;915-917.
35. Tuomanen E. Molecular mechanisms of inflammation in experimental pneumococcal meningitis. Pediatr Infect Dis. 6:1987;1146-1149.
36. Leib S.L., Leppert D., Clements J., Tauber M.G. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 68:2000;615-620.
37. Saravolatz L.D., Manzor O., VanderVelde N., Pawlak J., Belian B. Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. Clin Infect Dis. 36:2003;40-45.
38. Kaplan S.L. Clinical manifestations, diagnosis, and prognostic factors of bacterial meningitis. Infect Dis Clin North Am. 13:1999;579-590.
39. Portnoy J.M., Olsen L.C. Normal cerebrospinal fluid values in children: another look. Pediatrics. 75:1985;484-487.
40. Rodriguez A.F., Kaplan S.L., Mason E.O. Jr. Cerebrospinal fluid values in the very low birth weight infant. J Pediatr. 116:1990;971-974.
41. Feldman W.E. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr. 88:1976;549-552.
42. Pollard A.J., Probe G., Trombley C., et al. Evaluation of a diagnostic polymerase chain reaction assay for Neisseria meningitidis in North America and field experience during an outbreak. Arch Pathol Lab Med. 126:2002;1209-1215.
43. Margall Coscojuela N., Majo Moreno M., Latorre Otin C., Fontanals Amyerich D., Dominguez Garcia A., Prats Pastor G. Use of universal PCR on cerebrospinal fluid to diagnose bacterial meningitis in culture-negative patients. Eur J Clin Microbiol Infect Dis. 21:2002;67-69.
44. Koedel U., Scheld W.M., Pfister H.W. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis. 2:2002;721-736.
45. Converse G.M., Gwaltney J.M. Jr, Strassburg D.A., et al. Alteration of cerebrospinal fluid findings by partial treatment of bacterial meningitis. J Pediatr. 83:1973;220-225.
46. Moller K., Larsen F.S., Bie P., Skinhoj P. The syndrome of inappropriate secretion of antidiuretic hormone and fluid restriction in meningitis-how strong is the evidence? Scand J Infect Dis. 33:2001;13-26.
47. Powell K.R., Sugarman L.I., Eskenazi A.E., et al. Normalization of plasma arginine vasopressin concentrations when children with meningitis are given maintenance plus replacement fluid therapy. J Pediatr. 117:1990;515-522.
48. Singhi S.C., Singhi P.D., Srinivas B., et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatr Infect Dis J. 14:1995;495-503.
49. Duke T., Mokela D., Frank D., et al. Management of meningitis in children with oral fluid restriction or intravenous fluid at maintenance volumes: a randomised trial. Ann Trop Paediatr. 22:2002;145-157.
50. Sell S.H. Long term sequelae of bacterial meningitis in children. Pediatr Infect Dis. 2:1983;90-93.
51. Auslander M.C., Meskan M.E. The pattern and stability of post meningitic hearing loss in children. Laryngoscope. 98:1988;940-948.
52. Graham D.R., Band J.D. Citrobacter diversus brain abscess and meningitis in neonates. JAMA. 245:1981;1923-1925.
53. Snedecker J.D., Kaplan S.L., Dodge P.R., et al. Subdural effusion and its relationship with neurologic sequelae of bacterial meningitis in infancy: a prospective study. Pediatrics. S6:1990;163-170.
54. Feldman W.E. Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis. N Engl J Med. 296:1977;433-435.
55. Waage A., Halstensen A., Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1:1987;355-357.
56. Girgis N.L., Farid Z., Makhail I.A., et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J. 8:1989;848-851.
57. Kanra G.Y., Ozen H., Secmeer G., et al. Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J. 14:1995;490-494.
58. Kennedy W.A., Hoyt M.J., McCracken G.H. Jr. The role of corticosteroid therapy in children with pneumococcal meningitis. Amer J Dis Child. 145:1991;1374-1378.
59. Kilpi T., Peltola H., Jauhiainen T., et al. Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. Pediatr Infect Dis J. 14:1995;270-278.
60. Lebel M.H., Freij B.J., Syrogiannopoulos G.A., et al. Dexamethasone therapy for bacterial meningitis; results of two double-blind, placebo-controlled trials. N Engl J Med. 319:1988;964-971.
61. McCracken G.H. Jr, Lebel M.H. Dexamethasone therapy for bacterial meningitis in infants and children. Am J Dis Child. 143:1989;287.
62. Schaad U.B., Lips U., Gnehm H.E., et al. Dexamethasone therapy for bacterial meningitis in children. Lancet. 342:1993;457-461.
63. Odio C.M., Faingezicht I., Paris M., et al. The beneficial effects of early dexamethasone administration on infants and children with bacterial meningitis. N Engl J Med. 324:1991;1525-1531.
64. McIntyre P.B., Berkey C.S., King S.M., et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA. 278:1997;925-931.
65. McCracken G.H. Jr. New developments in the management of children with bacterial meningitis. Pediatr Infect Dis. 3:1984;532-534.
66. Andes D.R., Craig W.A. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Amer. 13:1999;595-618.
67. Ahmed A., Jafri H., Lutsar I., et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 43:1999;876-881.
68. Rodríguez-Cerrato V., McCoig C.C., Michelow I.C., et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 45:2001;3092-3097.
69. Lutsar I., McCracken G.H. Jr, Friedland I.R. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 27:1998;1117-1127.
70. Sáez-Llorens X., O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J. 20:2001;356-361.
71. Klugman K.P., Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother. 39:1995;1988-1992.
72. Martínez-Lacasa J., Cabellos C., Martos A., et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother. 49:2002;507-513.
73. Fink S., Karp W., Robertson A. Ceftriaxone effect on bilirubin-albumin binding. Pediatrics. 80:1987;873-875.
74. Del Rio M., Chrane D., Shelton S., et al. Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children. Lancet. 1:1983;1241-1244.
75. Lebel M.H., Hoyt M.J., McCracken G.H. Jr. Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis. J Pediatr. 114:1989;1049-1054.
76. Hussein A.A., Abdel Rahman S.I. Meningococcal meningitis epidemic: a new role for single-dose oily chloramphenicol. Saudi Med J. 23:2002;797-801.
77. Jacobs M.R., Koornhof H.J., Robins-Browne R.M., et al. Emergence of multiply resistant pneumococci. N Engl J Med. 299:1978;735-740.
78. Arditi M., Mason E.O., Bradley J.S., et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics. 102:1998;1087-1097.
79. McCracken G.H. Jr. Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J. 14:1995;424-429.
80. Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr. 161:2002;188-195.
81. Novak R., Henriques B., Charpentier E., Normark S., Tuomanen E. Emergence of vancomycin tolerante in Streptococcus pneumoniae. Nature. 399:1999;590-593.
82. Mitchell L., Tuomanen E.I. Vancomycin-tolerant Streptococcus pneumoniae and its clinical significance. Pediatr Infect Dis J. 20:2001;531-533.
83. Rodriguez-Cerrato V., McCoig C.C., Saavedra J., et al. Garenoxacin and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother. 47:2003;211-215.
84. Sáez-Llorens X., McCoig C., Feris J.M., et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J. 21:2002;14-22.
85. Kyaw M.H., Bramley J.C., Clark S., Christie P., Jones I.G., Campbell H. Prevalence of moderate penicillin resistant invasive Neisseria meningitides infection in Scotland, 1994-1999. Epidemiol Infect. 128:2002;149-156.
86. Richter S.S., Gordon K.A., Rhomberg P.R., Pfaller M.A., Jones R.N. Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-1999. Diagn Microbiol Infect Dis. 41:2001;83-88.
87. Kaplan S.L. Adjunctive therapy in meningitis. Adv Pediatr Infect Dis. 10:1995;167-186.
88. Ashwal S., Perkin R.M., Thompson J.R., et al. Bacterial meningitis in children: current concepts of neurologic management. Curr Prob Pediatr. 24:1994;267-284.
89. Syrogiannopoulos G.A., Lourida A.N., Theodoridou M.C., et al. Dexamethasone therapy for bacterial meningitis in children: 2 versus 4 day regimen. J Infect Dis. 169:1994;853-858.
90. Wald E.R., Kaplan S.L., Mason E.O., et al. Dexamethasone therapy for children with bacterial meningitis. Pediatrics. 95:1995;21-28.
91. Meli D.N., Christen S., Leib S.L., Tauber M.G. Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae. Curr Opin Infect Dis. 15:2002;253-257.
92. Nau R., Bruck W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci. 25:2002;38-45.
93. Molyneux E.M., Walsh A.L., Forsyth H., et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 360:2002;211-218.
94. McCracken G.H. Jr. Rich nations, poor nations, and bacterial meningitis. Lancet. 360:2002;183.
95. de Gans J., van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 347:2002;1549-1556.
96. Levin M., Quint P.A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. Lancet. 356:2000;961-967.
97. Giroir B.P., Quint P.A., Barton P., et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet. 350:1997;1439-1443.
98. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
99. Black S.B., Shinefield H., Fireman B., et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis. 10:1991;97-104.
100. Peltola H., Kilpi T., Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugated vaccines. Lancet. 340:1992;592-594.
101. Chonghaile C.N. Meningitis in Africa. Tackling W135. Lancet. 360:2002;2054-2055.
102. Jodar L., Feavers I.M., Salisbury D., Granoff D.M. Development of vaccines against meningococcal disease. Lancet. 359:2002;1499-1508.
103. Salleras L., Dominguez A., Prats G., Parron I., Muñoz P. Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people. Epidemiol Community Health. 55:2001;283-287.
104. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health. 37:2001;S34-36.
105. Kaplan S.L. Management of pneumococcal meningitis. Pediatr Infect Dis J. 21:2002;589-591.
106. Baucher H. Use of the new pneumococcal conjugate vaccine in the USA. Arch Dis Child. 83:2000;396.
107. Baker C.J. Prevention of neonatal group B streptococcal disease. Pediatr Infect Dis. 2:1983;1-5.
108. Baltimore R.S., Huie S.M., Meek J.I., Schuchat A., O'Brien K.L. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics. 108:2001;1094-1098.
109. Baker C.J., Paoletti L.C., Rench M.A., et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 182:2000;1129-1138.
110. Schwartz B., Al-Ruwais A., As Ashi J., et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet. 1:1988;1239-1242.
111. Peltola H. Prophylaxis of bacterial meningitis. Infect Dis Clin North Amer. 13:1999;685-710.